• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆囊切除患者中氟罗沙星的药代动力学及胆汁浓度

Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.

作者信息

Hayton W L, Vlahov V, Bacracheva N, Viachki I, Portmann R, Muirhead G, Stoeckel K, Weidekamm E

机构信息

College of Pharmacy, Washington State University, Pullman 99164-6510.

出版信息

Antimicrob Agents Chemother. 1990 Dec;34(12):2375-80. doi: 10.1128/AAC.34.12.2375.

DOI:10.1128/AAC.34.12.2375
PMID:2128442
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC172064/
Abstract

Patients with biliary tract infections received 800 mg of fleroxacin orally once daily on five consecutive days; cholecystectomy was on day 3. Starting on the day when dose 5 was administered, serial blood and T-drain bile samples were taken for 72 h and urine was collected for 96 h. The mean (+/- the standard deviation) peak concentration in plasma was 8.2 +/- 4.0 mg/liter at 8.3 h. The harmonic mean elimination half-life was 10.5 h, which is comparable to that reported for healthy volunteers. This increase resulted from reduced renal clearance (mean [+/- standard deviation], 38 +/- 22 ml/min), as the volume of distribution in the patients (1.4 +/- 0.7 liter/kg) did not differ from that reported for healthy subjects. Maximum concentrations in T-drain bile were high (median, 22.1 mg/liter) and exceeded those measured in plasma by a factor of 2 to 3; the individual ratios of the area under the curve for bile divided by that for plasma ranged from 1.3 to 9.9. As observed in healthy volunteers, the major pathway for elimination of fleroxacin was via the kidneys. The fraction of dose 5 eliminated in the 0- to 24-h urine was reduced, however, and the fraction of the dose in the urine as the N-demethyl and N-oxide metabolites was elevated. At the dose regimen used in this study, the MICs for most pathogens that cause biliary tract infections were surpassed in plasma and bile for more than 24 h.

摘要

胆道感染患者连续5天每天口服800毫克氟罗沙星;在第3天进行胆囊切除术。从给予第5剂药物的当天开始,连续72小时采集系列血液和T形引流胆汁样本,并收集96小时尿液。血浆中平均(±标准差)峰浓度在8.3小时时为8.2±4.0毫克/升。谐波平均消除半衰期为10.5小时,与健康志愿者报告的半衰期相当。这种增加是由于肾清除率降低(平均[±标准差],38±22毫升/分钟),因为患者的分布容积(1.4±0.7升/千克)与健康受试者报告的分布容积没有差异。T形引流胆汁中的最大浓度很高(中位数为22.1毫克/升),超过血浆中测得浓度的2至3倍;胆汁曲线下面积与血浆曲线下面积的个体比值范围为1.3至9.9。正如在健康志愿者中观察到的那样,氟罗沙星的主要消除途径是通过肾脏。然而,第5剂药物在0至24小时尿液中消除的比例降低,尿液中作为N-去甲基和N-氧化物代谢物的剂量比例升高。在本研究使用的给药方案下,血浆和胆汁中超过24小时超过了大多数引起胆道感染病原体的最低抑菌浓度。

相似文献

1
Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.胆囊切除患者中氟罗沙星的药代动力学及胆汁浓度
Antimicrob Agents Chemother. 1990 Dec;34(12):2375-80. doi: 10.1128/AAC.34.12.2375.
2
The metabolism and pharmacokinetics of fleroxacin in healthy subjects.氟罗沙星在健康受试者中的代谢及药代动力学
J Antimicrob Chemother. 1988 Oct;22 Suppl D:191-4. doi: 10.1093/jac/22.supplement_d.191.
3
Single and multiple dose pharmacokinetics of fleroxacin.氟罗沙星的单剂量和多剂量药代动力学
J Antimicrob Chemother. 1988 Oct;22 Suppl D:145-54. doi: 10.1093/jac/22.supplement_d.145.
4
Penetration of ciprofloxacin and fleroxacin into biliary tract.环丙沙星和氟罗沙星在胆道中的渗透性。
Antimicrob Agents Chemother. 1996 Mar;40(3):787-91. doi: 10.1128/AAC.40.3.787.
5
Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.氟罗沙星在健康男性志愿者中的临床药代动力学及耐受性
J Antimicrob Chemother. 1988 Oct;22 Suppl D:133-44. doi: 10.1093/jac/22.supplement_d.133.
6
Metabolism of fleroxacin in man.氟罗沙星在人体内的代谢。
J Antimicrob Chemother. 1988 Oct;22 Suppl D:169-78. doi: 10.1093/jac/22.supplement_d.169.
7
First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.首次群体药代动力学分析显示,与健康志愿者相比,囊性纤维化患者的喹诺酮类代谢产物生成和清除增加。
Eur J Pharm Sci. 2018 Oct 15;123:416-428. doi: 10.1016/j.ejps.2018.07.054. Epub 2018 Aug 1.
8
Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.新型三氟喹诺酮类药物氟罗沙星及其代谢产物的处置。老年患者的药代动力学。
Clin Pharmacokinet. 1990 Jul;19(1):80-8. doi: 10.2165/00003088-199019010-00006.
9
Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.新型三氟喹诺酮类药物氟罗沙星及其代谢物的处置。肾衰竭时的药代动力学及血液透析的影响。
Clin Pharmacokinet. 1990 Jul;19(1):67-79. doi: 10.2165/00003088-199019010-00005.
10
Altered disposition of fleroxacin in patients with cystic fibrosis.囊性纤维化患者中氟罗沙星的处置改变。
Clin Pharmacol Ther. 1990 May;47(5):618-28. doi: 10.1038/clpt.1990.83.

引用本文的文献

1
Simplifying the Extended Clearance Concept Classification System (EC3S) to Guide Clearance Prediction in Drug Discovery.简化扩展清除概念分类系统 (EC3S) 以指导药物发现中的清除预测。
Pharm Res. 2023 Apr;40(4):937-949. doi: 10.1007/s11095-023-03482-4. Epub 2023 Mar 1.
2
Effects of surgery on the pharmacokinetic parameters of drugs.手术对药物药代动力学参数的影响。
Clin Pharmacokinet. 1998 Oct;35(4):293-312. doi: 10.2165/00003088-199835040-00003.
3
Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.利用正电子发射断层扫描研究健康人体受试者中[18F]氟罗沙星的药代动力学。
Antimicrob Agents Chemother. 1993 Oct;37(10):2144-52. doi: 10.1128/AAC.37.10.2144.
4
Biliary excretion of rufloxacin in humans.鲁氟沙星在人体中的胆汁排泄。
Antimicrob Agents Chemother. 1993 Dec;37(12):2545-9. doi: 10.1128/AAC.37.12.2545.
5
Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.大鼠体内司帕沙星、氟罗沙星和环丙沙星的肠道排泄情况。
Antimicrob Agents Chemother. 1995 Jan;39(1):99-102. doi: 10.1128/AAC.39.1.99.
6
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.氟罗沙星。对其在各种感染中的药理学及治疗效果的综述。
Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010.
7
Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.用正电子发射断层扫描研究18F标记的氟罗沙星在大肠杆菌感染兔体内的药代动力学。
Antimicrob Agents Chemother. 1992 Oct;36(10):2286-92. doi: 10.1128/AAC.36.10.2286.

本文引用的文献

1
Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.甲磺酸培氟沙星在小鼠、大鼠、犬、猴及人体内的吸收、分布、代谢转归及消除
Antimicrob Agents Chemother. 1984 Apr;25(4):463-72. doi: 10.1128/AAC.25.4.463.
2
Concentrations of ciprofloxacin in human liver, gallbladder, and bile after oral administration.
Eur J Clin Pharmacol. 1987;32(2):217-8. doi: 10.1007/BF00542200.
3
Concentration of norfloxacin in human gallbladder tissue and bile after single-dose oral administration.单次口服给药后诺氟沙星在人体胆囊组织和胆汁中的浓度。
Antimicrob Agents Chemother. 1987 Feb;31(2):352-3. doi: 10.1128/AAC.31.2.352.
4
Biliary tract excretion of ofloxacin in man.氧氟沙星在人体中的胆道排泄。
Drugs. 1987;34 Suppl 1:39-43. doi: 10.2165/00003495-198700341-00010.
5
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.新型抗菌4-喹诺酮类药物的临床药代动力学
Clin Pharmacokinet. 1988 Feb;14(2):96-121. doi: 10.2165/00003088-198814020-00003.
6
Hepatobiliary kinetics and excretion of ciprofloxacin.环丙沙星的肝胆动力学及排泄
Antimicrob Agents Chemother. 1988 Jul;32(7):982-5. doi: 10.1128/AAC.32.7.982.
7
Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.氟罗沙星:全球范围内对20807株临床分离菌的体外活性及与环丙沙星和诺氟沙星的比较
J Antimicrob Chemother. 1988 Oct;22 Suppl D:3-17. doi: 10.1093/jac/22.supplement_d.3.
8
The metabolism and pharmacokinetics of fleroxacin in healthy subjects.氟罗沙星在健康受试者中的代谢及药代动力学
J Antimicrob Chemother. 1988 Oct;22 Suppl D:191-4. doi: 10.1093/jac/22.supplement_d.191.
9
Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.氟罗沙星在健康男性志愿者中的临床药代动力学及耐受性
J Antimicrob Chemother. 1988 Oct;22 Suppl D:133-44. doi: 10.1093/jac/22.supplement_d.133.
10
Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.单次及多次服用400毫克和800毫克剂量氟罗沙星后的药代动力学及组织渗透情况。
Antimicrob Agents Chemother. 1988 Oct;32(10):1515-20. doi: 10.1128/AAC.32.10.1515.